支气管内瘤内化疗的安全性与可行性多中心前瞻性试点研究
这项多中心前瞻性试点研究纳入23例非小细胞肺癌合并恶性气道梗阻患者,在硬质支气管镜再通后使用新型微注射导管向气道壁注射紫杉醇1.5 mg。
要点
- 再通后经新型导管气道壁注射紫杉醇1.5 mg,未观察到不良事件或器械相关不良效应。
- 术后狭窄程度较术前显著降低(25%-50% vs 75%-90%,P < .001),6周时维持不变。
- 所有完成操作患者均无需进一步干预或气道支架置入。
核心结论
- 非小细胞肺癌合并恶性气道梗阻患者,再通后注射紫杉醇是安全可行的。
研究设计与样本
- 多中心前瞻性试点研究,2014年7月至2016年6月纳入23例非小细胞肺癌合并恶性气道梗阻患者。
- 患者接受硬质支气管镜再通后,使用新型微注射导管注射紫杉醇1.5 mg。
主要发现
- 未发生不良事件、严重不良事件或非预期器械不良效应。
- 所有患者平均注射3.4次,紫杉醇总剂量为1.5 mg。
- 术后狭窄程度显著低于术前(25%-50% vs 75%-90%;P < .001),6周时仍为25%-50%。
- 无参与者需要进一步干预或气道支架置入。
关键数值与推荐
- 主要终点为安全性(不良事件、严重不良事件、非预期器械不良效应)和可行性(注射次数、注射成功率)。
- 次要终点包括气道通畅改善、生活质量指标及是否需要进一步干预和/或支架置入。
- 紫杉醇注射总剂量为1.5 mg,平均注射3.4次。
临床怎么用
- 对于非小细胞肺癌合并恶性气道梗阻患者,可在硬质支气管镜再通后考虑经新型导管行瘤内紫杉醇注射。
- 该操作在本研究条件下未观察到安全性信号,且可改善气道狭窄并减少后续干预需求。
局限性
- 随访至6周,缺乏长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignant airway obstruction (MAO) occurs in 30% of patients with advanced-stage lung cancer, leading to debilitating dyspnea, cough, and hemoptysis. Other than recanalization of the airways, these patients lack long-lasting palliative therapy. The goal of this study was to determine the safety and feasibility of local injection of paclitaxel into the airway wall with a novel microinjection catheter. METHODS: In this multicentered prospective trial, 23 patients with non-small cell lung cancer and MAO were enrolled from July 2014 through June 2016 to undergo rigid bronchoscopy with recanalization, followed by injection of 1.5 mg of paclitaxel with a novel injection catheter. Primary end points consisted of safety (adverse events, severe adverse events, and unanticipated adverse device effects) as well as feasibility (number of injections, injection success). Secondary end points consisted of airway patency improvement, quality of life metrics, and need for further interventions and/or stenting. RESULTS: Nineteen patients underwent rigid bronchoscopy with successful recanalization and paclitaxel injection. There were no adverse events, severe adverse events, or unanticipated adverse device effects. There was an average of 3.4 injections given for a total dose of 1.5 mg of paclitaxel in all patients. There was significantly less stenosis postprocedure vs preprocedure (25%-50% vs 75%-90%; P < .001), which was unchanged at 6 weeks (25%-50%). None of the participants required further interventions or airway stenting. CONCLUSIONS: The injection of paclitaxel after recanalization of MAO in patients with non-small cell lung cancer is safe and feasible, using a novel airway injection device. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02066103; URL: www.clinicaltrials.gov.
引用
- Yarmus L, Mallow C, Akulian J, et al. Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy. Chest. 2019. PMID: 30776363. doi:10.1016/j.chest.2019.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。